Ashkon Software

   







 


TEAR - TearLab Corporation

TearLab Corporation logo TearLab Corporation (TEAR) is a medical technology company that develops and commercializes non-invasive tear testing solutions to aid in the diagnosis and management of dry eye disease. The company's flagship product is the TearLab Osmolarity System, which measures the osmolarity of tears, an important indicator of dry eye disease.

As of its most recent financial reports, TearLab reported total revenue of $1.8 million for the nine months ended September 30, 2021, compared to $3.3 million for the same period in the previous year. The company reported a net loss of $4.6 million for the nine months ended September 30, 2021, compared to a net loss of $8.7 million for the same period in the previous year.

TearLab's strategy is focused on expanding the adoption of its TearLab Osmolarity System in the diagnosis and management of dry eye disease. The company is also working to develop and commercialize new products in the field of ophthalmology and to expand its product offerings beyond dry eye disease.

Investing in medical technology companies like TearLab carries market risks, including the risk of market volatility, changes in healthcare regulations, and competition from other companies in the industry. Investors should carefully consider these risks before investing in TEAR and consult with a financial advisor to determine if it is an appropriate investment for their portfolio. They should also review the company's public disclosures and financial statements to gain a better understanding of its financial performance and risks.

 



 

 

 
Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer